دورية أكاديمية

How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis

التفاصيل البيبلوغرافية
العنوان: How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis
المؤلفون: Randee J Kastner, Elisa Sicuri, Christopher M Stone, Gabriel Matwale, Ambrose Onapa, Fabrizio Tediosi
المصدر: Public Library of Science, PLOS Neglected Tropical Diseases. 11(9):1-20
سنة النشر: 2017
الوصف: Introduction: Lymphatic filariasis (LF), a neglected tropical disease (NTD) preventable through mass drug administration (MDA), is one of six diseases deemed possibly eradicable. Previously we developed one LF elimination scenario, which assumes MDA scale-up to continue in all countries that have previously undertaken MDA. In contrast, our three previously developed eradication scenarios assume all LF endemic countries will undertake MDA at an average (eradication I), fast (eradication II), or instantaneous (eradication III) rate of scale-up. In this analysis we use a micro-costing model to project the financial and economic costs of each of these scenarios in order to provide evidence to decision makers about the investment required to eliminate and eradicate LF. Methodology/Key findings: Costing was undertaken from a health system perspective, with all results expressed in 2012 US dollars (USD). A discount rate of 3% was applied to calculate the net present value of future costs. Prospective NTD budgets from LF endemic countries were reviewed to preliminarily determine activities and resources necessary to undertake a program to eliminate LF at a country level. In consultation with LF program experts, activities and resources were further reviewed and a refined list of activities and necessary resources, along with their associated quantities and costs, were determined and grouped into the following activities: advocacy and communication, capacity strengthening, coordination and strengthening partnerships, data management, ongoing surveillance, monitoring and supervision, drug delivery, and administration. The costs of mapping and undertaking transmission assessment surveys and the value of donated drugs and volunteer time were also accounted for. Using previously developed scenarios and deterministic estimates of MDA duration, the financial and economic costs of interrupting LF transmission under varying rates of MDA scale-up were then modelled using a micro-cost
نوع الوثيقة: redif-article
اللغة: English
DOI: 10.1371/journal.pntd.0005
الإتاحة: https://ideas.repec.org/a/plo/pntd00/0005934.html
رقم الأكسشن: edsrep.a.plo.pntd00.0005934
قاعدة البيانات: RePEc
الوصف
DOI:10.1371/journal.pntd.0005